Charu Aggarwal1, Mary W Redman2, Primo N Lara3, Hossein Borghaei4, Philip Hoffman5, Jeffrey D Bradley6, Alfred J Newman7, Marvin J Feldman8, Katherine Minichiello2, Jieling Miao2, Philip C Mack3, Vassiliki A Papadimitrakopoulou9, Roy S Herbst10, Karen Kelly3, David R Gandara4. 1. University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: charu.aggarwal@uphs.upenn.edu. 2. SWOG Statistics and Data Management Center at Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. University of California Davis Comprehensive Cancer Center, Sacramento, California. 4. Fox Chase Cancer Center, Philadelphia, Pennsylvania. 5. University of Chicago, Chicago, Illinois. 6. Washington University Medical Center, St. Louis, Missouri. 7. Southeast Clinical Onc Research Consortium NCORP/ Novant Health Presbyterian Medical Center, Charlotte, North Carolina. 8. Sinai Hospital Cancer Institute, Baltimore, Maryland. 9. MD Anderson Cancer Center, Houston, Texas. 10. Yale Cancer Center, New Haven, Connecticut.
Abstract
BACKGROUND: S1400D is a biomarker-driven therapeutic substudy of Lung-MAP evaluating the fibroblast growth factor (FGF) receptor (FGFR) inhibitor AZD4547 in patients with FGF pathway-activated squamous cell. This is the first phase II trial to evaluate AZD4547 as a targeted approach in patients with previously treated FGFR-altered squamous cell NSCLC and is the first demonstration of successful implementation and conduct of a national umbrella protocol in this disease setting. METHODS: Eligible patients had tumoral FGFR alteration or mutation and had progressive disease after at least one line of platinum-based systemic therapy. Patients received AZD4547 80 mg twice daily orally. Primary endpoint was response by Response Evaluation Criteria in Solid Tumors version 1.1; secondary endpoints included progression-free survival, overall survival, and duration of response (DoR). RESULTS: Ninety-two patients were assigned to S1400D, 43 were enrolled, and 27 AZD4547-treated patients were evaluable. Evaluable patients were predominantly white (n = 24, 89%), median age 66 years (range, 49-88 years old), and female (n = 7, 26%). FGFR alterations included FGFR1 amplification (n = 23; 85%), FGFR3 amplification (n = 2; 7%), FGFR3 S249C (n = 2; 7%), and FGFR3 fusion (n = 1; 4%). Treatment with ADZ4547 was well tolerated; grade 3 adverse events occurred in six patients, and one patient had grade 4 sepsis. Of 27 response-evaluable patients, 1 patient with FGFR3 S249C had unconfirmed partial response with a DoR of 1.5 months and 1 patient with FGFR1 amplification had a confirmed partial response with a DoR of 2.9 months (7%, 95% confidence interval [CI]: 0%-17%). Median progression-free survival and overall survival for the AZD4547-treated cohort were 2.7 months (95% CI: 1.4- 4.5 months) and 7.5 months (95% CI: 3.7-9.3 months). CONCLUSIONS: AZD4547 had an acceptable safety profile but minimal activity in this predominantly FGFR1/FGFR3-amplified cohort. Evaluation of other targeted agents in Lung-MAP is ongoing.
BACKGROUND: S1400D is a biomarker-driven therapeutic substudy of Lung-MAP evaluating the fibroblast growth factor (FGF) receptor (FGFR) inhibitor AZD4547 in patients with FGF pathway-activated squamous cell. This is the first phase II trial to evaluate AZD4547 as a targeted approach in patients with previously treated FGFR-altered squamous cell NSCLC and is the first demonstration of successful implementation and conduct of a national umbrella protocol in this disease setting. METHODS: Eligible patients had tumoral FGFR alteration or mutation and had progressive disease after at least one line of platinum-based systemic therapy. Patients received AZD4547 80 mg twice daily orally. Primary endpoint was response by Response Evaluation Criteria in Solid Tumors version 1.1; secondary endpoints included progression-free survival, overall survival, and duration of response (DoR). RESULTS: Ninety-two patients were assigned to S1400D, 43 were enrolled, and 27 AZD4547-treated patients were evaluable. Evaluable patients were predominantly white (n = 24, 89%), median age 66 years (range, 49-88 years old), and female (n = 7, 26%). FGFR alterations included FGFR1 amplification (n = 23; 85%), FGFR3 amplification (n = 2; 7%), FGFR3 S249C (n = 2; 7%), and FGFR3 fusion (n = 1; 4%). Treatment with ADZ4547 was well tolerated; grade 3 adverse events occurred in six patients, and one patient had grade 4 sepsis. Of 27 response-evaluable patients, 1 patient with FGFR3 S249C had unconfirmed partial response with a DoR of 1.5 months and 1 patient with FGFR1 amplification had a confirmed partial response with a DoR of 2.9 months (7%, 95% confidence interval [CI]: 0%-17%). Median progression-free survival and overall survival for the AZD4547-treated cohort were 2.7 months (95% CI: 1.4- 4.5 months) and 7.5 months (95% CI: 3.7-9.3 months). CONCLUSIONS: AZD4547 had an acceptable safety profile but minimal activity in this predominantly FGFR1/FGFR3-amplified cohort. Evaluation of other targeted agents in Lung-MAP is ongoing.
Authors: Paul R Gavine; Lorraine Mooney; Elaine Kilgour; Andrew P Thomas; Katherine Al-Kadhimi; Sarah Beck; Claire Rooney; Tanya Coleman; Dawn Baker; Martine J Mellor; A Nigel Brooks; Teresa Klinowska Journal: Cancer Res Date: 2012-02-27 Impact factor: 12.701
Authors: Roy S Herbst; David R Gandara; Fred R Hirsch; Mary W Redman; Michael LeBlanc; Philip C Mack; Lawrence H Schwartz; Everett Vokes; Suresh S Ramalingam; Jeffrey D Bradley; Dana Sparks; Yang Zhou; Crystal Miwa; Vincent A Miller; Roman Yelensky; Yali Li; Jeff D Allen; Ellen V Sigal; David Wholley; Caroline C Sigman; Gideon M Blumenthal; Shakun Malik; Gary J Kelloff; Jeffrey S Abrams; Charles D Blanke; Vassiliki A Papadimitrakopoulou Journal: Clin Cancer Res Date: 2015-02-13 Impact factor: 12.531
Authors: Jonathan Weiss; Martin L Sos; Danila Seidel; Martin Peifer; Thomas Zander; Johannes M Heuckmann; Roland T Ullrich; Roopika Menon; Sebastian Maier; Alex Soltermann; Holger Moch; Patrick Wagener; Florian Fischer; Stefanie Heynck; Mirjam Koker; Jakob Schöttle; Frauke Leenders; Franziska Gabler; Ines Dabow; Silvia Querings; Lukas C Heukamp; Hyatt Balke-Want; Sascha Ansén; Daniel Rauh; Ingelore Baessmann; Janine Altmüller; Zoe Wainer; Matthew Conron; Gavin Wright; Prudence Russell; Ben Solomon; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Steinar Sollberg; Odd Terje Brustugun; Walburga Engel-Riedel; Corinna Ludwig; Iver Petersen; Jörg Sänger; Joachim Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle Heideman; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; Michael Hallek; Rameen Beroukhim; William Pao; Bert Klebl; Matthias Baumann; Reinhard Buettner; Karen Ernestus; Erich Stoelben; Jürgen Wolf; Peter Nürnberg; Sven Perner; Roman K Thomas Journal: Sci Transl Med Date: 2010-12-15 Impact factor: 17.956
Authors: Yi-Mi Wu; Fengyun Su; Shanker Kalyana-Sundaram; Nickolay Khazanov; Bushra Ateeq; Xuhong Cao; Robert J Lonigro; Pankaj Vats; Rui Wang; Su-Fang Lin; Ann-Joy Cheng; Lakshmi P Kunju; Javed Siddiqui; Scott A Tomlins; Peter Wyngaard; Seth Sadis; Sameek Roychowdhury; Maha H Hussain; Felix Y Feng; Mark M Zalupski; Moshe Talpaz; Kenneth J Pienta; Daniel R Rhodes; Dan R Robinson; Arul M Chinnaiyan Journal: Cancer Discov Date: 2013-04-04 Impact factor: 39.397
Authors: Michael M Fisher; Gopika SenthilKumar; Rong Hu; Steve Goldstein; Irene M Ong; Margot C Miller; Sean R Brennan; Saakshi Kaushik; Lindsey Abel; Kwangok P Nickel; Gopal Iyer; Paul M Harari; Randall J Kimple; Andrew M Baschnagel Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-13 Impact factor: 7.038
Authors: Francesco Facchinetti; Antoine Hollebecque; Rastislav Bahleda; Yohann Loriot; Ken A Olaussen; Christophe Massard; Luc Friboulet Journal: Clin Cancer Res Date: 2019-10-04 Impact factor: 12.531
Authors: Gopika SenthilKumar; Michael M Fisher; Justin H Skiba; Margot C Miller; Sean R Brennan; Saakshi Kaushik; Samantha T Bradley; Colin A Longhurst; Darya Buehler; Kwangok P Nickel; Gopal Iyer; Randall J Kimple; Andrew M Baschnagel Journal: Mol Cancer Ther Date: 2020-05-05 Impact factor: 6.261
Authors: Mary W Redman; Vassiliki A Papadimitrakopoulou; Katherine Minichiello; Fred R Hirsch; Philip C Mack; Lawrence H Schwartz; Everett Vokes; Suresh Ramalingam; Natasha Leighl; Jeff Bradley; Jieling Miao; James Moon; Louise Highleyman; Crystal Miwa; Michael L LeBlanc; Shakun Malik; Vincent A Miller; Ellen V Sigal; Stacey Adam; David Wholley; Caroline Sigman; Beverly Smolich; Charles D Blanke; Karen Kelly; David R Gandara; Roy S Herbst Journal: Lancet Oncol Date: 2020-10-27 Impact factor: 41.316
Authors: Mikkel G Terp; Kirstine Jacobsen; Miguel Angel Molina; Niki Karachaliou; Hans C Beck; Jordi Bertran-Alamillo; Ana Giménez-Capitán; Andrés F Cardona; Rafael Rosell; Henrik J Ditzel Journal: NPJ Precis Oncol Date: 2021-07-15
Authors: Young K Chae; Fangxin Hong; Christos Vaklavas; Heather H Cheng; Peter Hammerman; Edith P Mitchell; James A Zwiebel; S Percy Ivy; Robert J Gray; Shuli Li; Lisa M McShane; Larry V Rubinstein; David Patton; P Mickey Williams; Stanley R Hamilton; Aaron Mansfield; Barbara A Conley; Carlos L Arteaga; Lyndsay N Harris; Peter J O'Dwyer; Alice P Chen; Keith T Flaherty Journal: J Clin Oncol Date: 2020-05-28 Impact factor: 44.544